Devices/drugs to remain under DG Sanco in newly approved EU Commission
This article was originally published in Clinica
Executive Summary
Oversight of medical device and drug policy in the EU is to remain with the European Commission’s health directorate (DG Sanco), and not with the industry directorate (DG ENTR). The news was announced just before the European Parliament today voted in favor of the new European Commission, which will be led by President Jean-Claude Juncker and officially begin work on 1 November. There were 423 votes for the new commission and its new college of commissioners, 209 votes against and 67 abstentions.